Using CRISPR-Cas9 to identify new gene drug targets
Researchers have used CRISPR-Cas9 to screen the genome for possible targets that could be used in potential treatments for muscular dystrophy.
List view / Grid view
Genomics is the branch of molecular biology concerned with the structure, function, evolution, and mapping of genomes.
Researchers have used CRISPR-Cas9 to screen the genome for possible targets that could be used in potential treatments for muscular dystrophy.
A study has shown that plasmids use type IV CRISPR-Cas against competing plasmids, leading the researchers to suggest the method as a novel way to tackle multi-drug resistant bacteria.
Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.
The UK government has invested £20 million into the COVID-19 Genomics UK Consortium, which will use whole genome sequencing to inform infection control measures and therapeutic developments.
Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
Researchers have shown a gene therapy to correct the genetic mutation that causes Danon disease is successful in pre-clinical trials.
Using a combination of Cas9 and Cas12a, Canadian researchers have enabled CRISPR methods to edit multiple genes at the same time.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
Researchers have identified that copper ions and their protein transporters, such as Atox1, are key to cancer cell movement and could be targeted by therapies.
Researchers have created a new technical resource atlas which maps the 15 distinct cell types involved in muscle repair for disease and therapy research.
A novel antibody has been shown to stimulate microglia to degrade amyloid plaques in a murine model of Alzheimer’s disease.
Researchers have successfully treated cardiac dysfuntion in mice models of Barth syndrome by using a gene therapy to replace TAZ.
A novel therapy, tested ex vivo, has been successful at correcting the dysfunctional body mechanism in Postural Orthostatic Tachycardia Syndrome (POTS).
International researchers have analysed nearly 1,900 brain samples to create the Brain Atlas, the latest database released by the Human Protein Atlas (HPA) project.